Citius Oncology, Inc. CTOR
Set alert
At close · Oct 30
After hours · Oct 30, 5:35 PM ET
- YTD
- -44.60%
- 1 year
- -67.98%
- Open
- 0.5274
- Prev close
- 0.5295
- Mkt cap
- 58.59M
- Vol
- 292.79K
- Avg vol
- 116.09K
- EPS
- -0.48
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.5001
- High
- 0.563
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.37
- Inst. own
- 0.70%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.13
- 200-d avg
- 7.55
- 1y target
- 3.00
News
5 days ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by…
5 days ago gurufocus.com
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIRÂ Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2
-
5 days ago benzinga.com
Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
itius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius
5 days ago prnewswire.com
Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026
CRANFORD, N.J., Oct. 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of…
2 weeks ago prnewswire.com
Citius Pharmaceuticals to Participate in October 2026 Investor Conferences
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the 2026 Maxim Growth Summit and the ThinkEquity Conference CRANFORD, N.J., Oct. 12, 2026 /PRNewswire/ -- Citius…
1 month ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-market session. The market value of their outstanding shares is at $14.8 million. Geovax Labs (NASDAQ:GOVX)…
1 month ago prnewswire.com
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Chairman and CEO Leonard Mazur to present and host one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference and Moody Capital Solutions 2026 Disruptive Growth &…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 163.4% to $2.56 during Monday's pre-market session. The company's market cap stands at $1.7 million. GlucoTrack (NASDAQ:GCTK) shares moved…
2 months ago benzinga.com
Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
HIVE Digital Technologies Ltd (NASDAQ: HIVE) rose in pre-market trading due to its subsidiary's new agreement. Other gainers include IP Strategy Holdings, INVO Fertility, My Size, Trugolf Holdings,…
-
2 months ago benzinga.com
Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly…
2 months ago prnewswire.com
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions…
2 months ago prnewswire.com
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2026 Expanded LYMPHIR commercial and…
2 months ago prnewswire.com
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
CRANFORD, N.J., Aug. 12, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius…
-
2 months ago benzinga.com
Citius Oncology Reports 78% QoQ Growth In New Institutional Accounts Ordering LYMPHIR; Near‑Universal Payer Coverage Expands Market Access With Initial CTCL Market Exceeding $400M
New institutional accounts ordering LYMPHIR increased 78% quarter over quarterLYMPHIR's near-universal payer coverage expands market accessInitial cutaneous T-cell lymphoma (CTCL) market for LYMPHIR…
2 months ago prnewswire.com
Citius Oncology Reports Strong Commercial Momentum for its Cancer Treatment
New institutional accounts ordering LYMPHIR increased 78% quarter over quarter LYMPHIR's near-universal payer coverage expands market access Initial cutaneous T-cell lymphoma (CTCL) market for…
3 months ago defenseworld.net
Citius Oncology (NASDAQ:CTOR) Stock Price Up 0.6% – Here’s What Happened
Citius Oncology, Inc. (NASDAQ: CTOR - Get Free Report)'s share price rose 0.6% during mid-day trading on Wednesday. The company traded as high as $0.6298 and last traded at $0.5732. Approximately…
-
3 months ago benzinga.com
Citius Oncology Expands LYMPHIR Launch Team Nationwide Ahead Of Full U.S. Deployment In August
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by AugustCRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology")…
3 months ago prnewswire.com
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology")…
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Seer (NASDAQ:SEER) shares rose 32.1% to $2.14 during Monday's pre-market session. The market value of their outstanding shares is at $89.0 million. Innovative Eyewear (NASDAQ:LUCY) stock rose…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi…
-
5 months ago benzinga.com
Citius Oncology Presents Phase 1 Clinical Data Of LYMPHIR In Combination With Pembrolizumab In Patients With Recurrent Or Refractory Gynecologic Malignancies At American Society Of Clinical Oncology Annual Meeting
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR),…
5 months ago prnewswire.com
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily…
5 months ago prnewswire.com
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor…
5 months ago prnewswire.com
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad payer coverage established with no…
5 months ago prnewswire.com
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5…
5 months ago prnewswire.com
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization
Avenue Capital Group to provide up to $25 Million via Senior Credit Facility with an initial $10 million tranche funded at closing; additional tranches subject to certain conditions Gross proceeds of…
6 months ago prnewswire.com
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international markets…
7 months ago prnewswire.com
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration CRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology,…
7 months ago prnewswire.com
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available CRANFORD, N.J., March 24, 2026 /PRNewswire/ -- Citius…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
7 months ago prnewswire.com
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data of University of Pittsburgh-led…
8 months ago prnewswire.com
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial response…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
1 year ago benzinga.com
Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday
Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday
1 year ago benzinga.com
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
1 year ago benzinga.com
This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
This Commercial Metals Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
1 year ago benzinga.com
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
This Deckers Outdoor Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
1 year ago benzinga.com
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session